A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman MW, Collins J, McSherry F, Boardman K, Davies DK, O'Brien CP, Ling W, Kleber H, Herman BH.
Yu E, et al.
Drug Alcohol Depend. 2008 Sep 1;97(1-2):158-68. doi: 10.1016/j.drugalcdep.2008.04.002. Epub 2008 May 27.
Drug Alcohol Depend. 2008.
PMID: 18508207
Free PMC article.
Clinical Trial.